JPRN-UMIN000000846已完成未知
Primary prevention of cerebrovascular and cardiovascular events with an oral antidiabetic agent in patients with type 2 diabetes at high risk for cerebral infarction - Primary prevention for high risk Type 2 Diabetes patients in Japan:PROFIT-J
PROFIT-J Study Steering Committee0 个研究点目标入组 500 人开始时间: 2007年10月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 55years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1 Current or past history of heart failure 2 History of treatment with a thiazolidine derivative within 8 weeks 3 Severe liver dysfunction:ALT>= 100 or viral hepatitis 4 Severe renal dysfunction:Cr>=2.5 5 Concerns about safety of a thiazolidine derivative 6 Concerns about safety of drugs to be studied 7 Cerebral hemorrhage 8 Manifest dementia 9 History of documented myocardial infarction or angina prior to registration 10 Those whom the principle investigators or other investigators consider unsuitable
研究者
相似试验
进行中（未招募）
不适用
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMIschaemic stroke or transient ischaemic attackMedDRA version: 7.0Level: PTClassification code 10008190EUCTR2005-003700-10-BEInstitut de Recherches Internationales Servier18,000
进行中（未招募）
不适用
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMIschaemic stroke or transient ischaemic attackMedDRA version: 7.0Level: PTClassification code 10008190EUCTR2005-003700-10-FIInstitut de Recherches Internationales Servier18,000
进行中（未招募）
不适用
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMEUCTR2005-003700-10-GRInstitut de Recherches Internationales Servier18,000
进行中（未招募）
不适用
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMIschaemic stroke or transient ischaemic attackMedDRA version: 7.0Level: PTClassification code 10008190EUCTR2005-003700-10-ATInstitut de Recherches Internationales Servier18,000
进行中（未招募）
不适用
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMIschaemic stroke or transient ischaemic attackMedDRA version: 7.0Level: PTClassification code 10008190EUCTR2005-003700-10-ESaboratorios Servier S.L.18,000